Puma Biotechnology’s (PBYI) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a research note published on Monday,Benzinga reports. They currently have a $7.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $3.02 on Monday. Puma Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $7.73. The stock’s 50-day moving average is $2.95 and its two-hundred day moving average is $2.99. The firm has a market cap of $148.25 million, a P/E ratio of 6.29 and a beta of 1.08. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. During the same period last year, the business earned $0.12 EPS. On average, analysts anticipate that Puma Biotechnology will post 0.31 earnings per share for the current fiscal year.

Institutional Trading of Puma Biotechnology

Several hedge funds have recently added to or reduced their stakes in PBYI. SG Americas Securities LLC acquired a new position in shares of Puma Biotechnology during the third quarter worth approximately $34,000. Franklin Resources Inc. bought a new position in Puma Biotechnology during the third quarter worth $41,000. Dynamic Technology Lab Private Ltd bought a new stake in Puma Biotechnology in the 3rd quarter valued at $44,000. Patriot Financial Group Insurance Agency LLC boosted its holdings in Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 8,000 shares during the period. Finally, Royce & Associates LP grew its position in Puma Biotechnology by 71.8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 8,427 shares during the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.